ANXA2 suppresses antiviral immunity by impeding STING Golgi translocation and disrupting the TBK1/IKKε-IRF3 axis

mice confirmed that ANXA2 deficiency enhances type I IFN production, limits viral replication, and improves survival following HSV-1 challenge. Collectively, our findings unveil a multifaceted role for ANXA2 in dampening host antiviral immunity by targeting both the STING trafficking and the TBK1/IKKε-IRF3 activation steps, highlighting it as a potential target for immunomodulatory antiviral strategies. IMPORTANCE: . By pinpointing ANXA2 as a key inhibitor of the cGAS-STING pathway, this research not only advances our understanding of immune regulation but also identifies ANXA2 as a potential therapeutic target for modulating antiviral defenses.